Characteristics of antiplatelet therapy resistance in patients with acute coronary syndrome

Abstract:

Antiplatelet therapy and revascularization are essential for the successful treatment of patients with acute coronary syndrome. Despite modern and timely medical treatment a certain proportion of patients with acute coronary ischemia will develop new atherothrombotic events. The development of new antiplatelet drugs, improvement in stent technology and care for these patients failed to eliminate the recurrence of ischemic events after the initial coronary incident. The struggle with this immense public health problem must be conducted on more levels in preventive, curative and rehabilitative medicine. At the time of the individualized approach to the treatment, there is a need for effective strategies for prevention and treatment of patients with acute coronary syndrome in order to reduce the risk of new ischemic events, without significantly increasing the risk of bleeding. Challenges in antiplatelet pharmacotherapy of these patients will eventually increase due to the aging population, the complexity of the disease and comorbidities.

Key words:
acute coronary syndrome; myocardial infarction; precision medicine; platelet aggregation inhibitors; treatment outcome